hronic migraine is a common and debilitating neurologic condition. 1 The frequency of migraine attacks along with associated symptoms (photophobia, phonophobia, nausea/vomiting) contribute to the substantial morbidity of this illness, impacting both health care resource use and quality of life. [2][3][4][5][6] Chronic migraine also has a high societal cost, given that its prevalence is highest during midlife-generally the most productive and demanding years. 1,2,7,8 Overall, annual direct and indirect costs from migraine are estimated to be $20 billion in the United States alone, a substantial portion of which stems from chronic migraine. [7][8][9][10] Chronic migraine is defined by the International Headache Society as 15 headache days or more occurring per month for at least 3 months. There must be at least 8 days that are considered migrainous in nature. 11 Refractory chronic migraine represents an important subset of chronic migraine patients who experience migraines despite treatment with first-line oral agents and lifestyle modification. 12,13 Multiple treatment options have been described for the prophylactic management of refractory chronic migraine. Among the most promising